CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00562419 |
Recruitment Status : Unknown
Verified October 2010 by Adnexus, A Bristol-Myers Squibb R&D Company.
Recruitment status was: Active, not recruiting
First Posted : November 22, 2007
Last Update Posted : October 27, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving CT-322 together with irinotecan may kill more tumor cells.
PURPOSE: This phase 2 trial is studying the side effects, tolerability, and efficacy of CT-322 when given alone and in combination with irinotecan to patients with glioblastoma multiforme.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain and Central Nervous System Tumors Recurrent Glioblastoma Multiforme | Drug: CT-322 Drug: irinotecan hydrochloride | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 72 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme |
Study Start Date : | October 2007 |
Estimated Primary Completion Date : | June 2011 |
Estimated Study Completion Date : | December 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
CT-322
|
Drug: CT-322
IV solution, weekly |
Experimental: 2
CT-322 and irinotecan hydrochloride
|
Drug: CT-322
IV solution, weekly Drug: irinotecan hydrochloride IV solution, biweekly |
- Safety and tolerability of CT-322 when administered alone or in combination with irinotecan hydrochloride (Part 1) [ Time Frame: 15 ± 5 days post the last dose of study drug ]
- Progression-free survival at 6 months (Part 2) [ Time Frame: Measured upon initiation of cycles 2, 3, 5, 7, 9, 11, and end of study ]
- To assess the plasma pharmacokinetics of CT-322 (Cmax, Tmax, AUC, T-HALF) derived from plasma concentration vs time for CT-322 given alone and in combination with irinotecan [ Time Frame: Part 1: cycle 1, days 1-3, day 5 or 6, days 8, 15, and 22; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. Part 2: cycle 1, days 1, 8, 15, and 22; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. ]
- To assess the presence of anti CT-322 antibodies [ Time Frame: Part 1: cycle 1, days 1 and 15; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. Part 2: cycle 1, days 1 and 15; cycles 2-4, 6, 9, and 12, day 1; EOS and follow up visits. ]
- To assess the biological activity of CT-322 as measured by plasma biological markers and neuroimaging [ Time Frame: Part 1: cycle 1, days 1, 2, 8, 15 and 22; cycles 2-4, 6, 9, and 12, day 1; EOS visit. Part 2: cycle 1, days 1, 8, 15 and 22; cycles 2-4, 6, 9, and 12 EOS visit. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS
- Histologically confirmed diagnosis of recurrent/progressive GBM presenting in first, second, or third relapse (progression following anti-cancer therapy other than surgery)
- Bidimensionally measurable recurrent or residual primary disease on contrast-enhanced MRI
PATIENT CHARACTERISTICS
Age:
• 18 and over
Hematopoietic:
- ANC ≥ 1,500/mL
- Platelets ≥ 100,000/mL
- Hemoglobin ≥ 9.0g/dL
Hepatic:
- AST and ALT ≤ 1.5 x ULN
- Bilirubin ≤ 1.5 x ULN
Coagulation:
• INR < 1.5 or PT within normal limits; and PTT within normal limits
Renal:
Creatinine ≤ 1.5 x ULN; Urine protein/creatinine ratio ≤ 1
Cardiovascular
- 2-dimensional echocardiogram or cardiac multigated acquisition (MUGA) scan demonstrating left ventricular ejection fraction within the institutional normal range.
- No coronary artery bypass graft, angioplasty, vascular stenting, myocardial infarction, unstable angina, congestive heart failure within the preceding 12 months.
- No thrombotic or embolic cerebrovascular accident, including transient ischemic attacks within the past 12 months and no conditions that would not permit the safe discontinuation of specified anti-platelet medications
- No intraparenchymal CNS hemorrhage, except for Grade 1 intraparenchymal hemorrhage in the immediate post-operative period or Grade 1 intraparenchymal hemorrhage that has been stable or improved
Immunologic:
• Not known to have human immunodeficiency virus infection (HIV) or active hepatitis B or C virus infection
Other:
- Negative pregnancy test within 72 hours prior to drug administration
- Not pregnant or breast feeding
- Fertile patients must agree to use effective methods of birth control and must agree to do so until at least 4 weeks after the last dose of drug administration
- No serious non-healing wound, ulcer or bone fracture or recent significant traumatic injury (within 4 weeks)
- Have ability to understand and sign an informed consent document
- Be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- No other malignancy within the past 3 years, except for basal cell skin cancer, cervical carcinoma in situ, or other primary malignancy that is not currently clinically significant or does not require active intervention
- No prior grade 3 or greater toxicity to irinotecan
- No other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that could increase the risks associated with study participation or study drug administration or could interfere with the interpretation of the study results and would make the patient inappropriate for study entry
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
- At least 4 weeks between prior biological or immunotherapy and recovered
Chemotherapy:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy and recovered (6 weeks for nitrosoureas), unless there is unequivocal evidence of tumor progression
Radiotherapy:
• At least 12 weeks from completion of standard, daily radiotherapy and recovered, unless any of the following occurs:
- New area of enhancement on MRI that is outside the radiotherapy field
- Biopsy-proven recurrent tumor
- Radiographic evidence of progressive tumor on 2 consecutive scans taken ≥ 4 weeks apart
Surgery
- At least 4 weeks since major surgery, open biopsy or significant traumatic injury and recovered
- At least 1 week since other prior biopsy
Other:
- Not concurrently enrolled in another therapeutic clinical trial involving ongoing therapy
- No prior treatment with VEGF or VEGFR inhibitors or vascular targeting/disrupting agents
- No prior CT-322 therapy
- No prior failure of irinotecan therapy
- No prior treatment with stereotactic radiosurgery, brachytherapy, or a surgically created resection cavity to support other anatomically localized therapies
- No severe or uncontrolled medical disease (uncontrolled diabetes, hypertension, serious infection > CTCAE grade 2, significant bleeding or platelet dysfunction, gastrointestinal bleed)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00562419
United States, California | |
University of California, San Diego | |
La Jolla, California, United States, 92037-0845 | |
United States, Kentucky | |
University of Kentucky | |
Lexington, Kentucky, United States, 40536 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02114 | |
United States, Michigan | |
Henry Ford Health System | |
Detroit, Michigan, United States, 48202 | |
United States, New York | |
SUNY Upstate Medical University | |
Syracuse, New York, United States, 13210 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Rhode Island | |
Rhode Island Hospital | |
Providence, Rhode Island, United States, 02903 | |
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
United States, Virginia | |
University of Virgina | |
Charlottesville, Virginia, United States, 22908 | |
United States, Wisconsin | |
University of Wisconsin Hospital | |
Madison, Wisconsin, United States, 53792 |
Responsible Party: | Medical Director, Adnexus, A Bristol-Myers Squibb R&D Company, Adnexus, A Bristol-Myers Squibb R&D Company |
ClinicalTrials.gov Identifier: | NCT00562419 History of Changes |
Other Study ID Numbers: |
CT-322.002 |
First Posted: | November 22, 2007 Key Record Dates |
Last Update Posted: | October 27, 2010 |
Last Verified: | October 2010 |
Additional relevant MeSH terms:
Glioblastoma Nervous System Neoplasms Central Nervous System Neoplasms Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms, Nerve Tissue Neoplasms by Site Nervous System Diseases Irinotecan Camptothecin Antineoplastic Agents, Phytogenic Antineoplastic Agents Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |